RGO:F:F-Regeneron Pharmaceuticals Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 996

Change

0.00 (0.00)%

Market Cap

USD 108.70B

Volume

1.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

N/A

USD 526.04B
NOVA:F Novo Nordisk A/S

N/A

USD 524.27B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 91.04B
CSJ:F CSL Limited

N/A

USD 91.04B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 31.06B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 30.44B
1AE:F Argen-X

N/A

USD 29.24B
1AEA:F argenx SE

N/A

USD 29.18B
0QF:F Moderna Inc

N/A

USD 25.22B
22UA:F BioNTech SE

N/A

USD 19.33B

ETFs Containing RGO:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.68% 75% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.68% 75% C 76% C+
Trailing 12 Months  
Capital Gain 43.21% 80% B- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.21% 80% B- 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 18.90% 83% B 84% B
Dividend Return 18.90% 83% B 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.37% 85% B 69% C-
Risk Adjusted Return 108.85% 100% F 97% N/A
Market Capitalization 108.70B 100% F 99% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.